摘要
卵巢恶性肿瘤的发病率位居我国女性生殖系统恶性肿瘤的第3位。其中,上皮性卵巢癌(EOC)的发病率最高,约占卵巢恶性肿瘤的70%。由于EOC患者早期临床症状缺乏特异性,导致70%EOC患者确诊时,已处于国际妇产科联盟(FIGO)临床分期的晚期。FIGO晚期EOC患者的5年总体生存率仅为30%~40%。随着近年基因检测技术的进步、靶向治疗药物的开发与临床应用,使EOC患者的疾病无进展生存(PFS)期逐渐延长。笔者拟就EOC患者基因突变、靶向药物治疗临床应用的最新研究进展现状进行阐述。
Ovarian cancer is top 3 female reproductive system carcinoma in China.Among ovarian cancer,epithelial ovarian cancer(EOC)has the highest incidence.Due to the lack of specific early clinical symptoms of EOC patients,70%of them were in the late clinical stage of Federation International of Gynecology and Obstetrics(FIGO)at the time of being diagnosed.The 5-year overall survival rate of patients with EOC was only 30%-40%.With development of gene detection technology,and development and clinical application of targeted drugs in recent years,the period of progression-free survival(PFS)of EOC patients is prolonged.The authors intend to review the latest research progresses in clinical application of gene mutation and targeted drug therapy in patients with EOC.
作者
林昌盛
战军
肖雪
Lin Changsheng;Zhan Jun;Xiao Xue(Department of Obstetrics and Gynecology,Reproductive Endocrine and Reproductive Medicine Regulation Research Laboratory,Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University),Ministry of Education,West China Second University Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China)
出处
《中华妇幼临床医学杂志（电子版）》
2023年第5期505-510,共6页
Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)
基金
国家自然科学基金项目(82071651)。
